New drug duo aims to wipe out lung cancer before surgery
NCT ID NCT07281209
First seen Jan 11, 2026 · Last updated May 16, 2026 · Updated 22 times
Summary
This study tests whether giving two drugs (SHR-A1811 and adebelimumab) before surgery can shrink or eliminate tumors in people with early-stage lung cancer that has a specific genetic change (HER2 alteration). About 40 adults with resectable non-small cell lung cancer will receive the combination, then have surgery to remove any remaining cancer. The main goal is to see how many patients have no cancer left at the time of surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.